Core-cyclical, ~3–5% as the anchor financial holding (not a satellite)
Next catalyst
2026-07-14 Q2'26 earnings (Street EPS $5.49)
Single biggest risk
Late-cycle credit normalization + net-interest-income roll-down if the Fed cuts
One-line thesis. JPMorgan is the best-run large bank in the world — FY25 net income $57B, 1Q26 ROTCE 23%, a fortress 14.3% CET1 capital ratio — trading at a reasonable ~14× forward earnings, so you are paid to own a genuine quality compounder with heavy capital return; the whole call rests on the credit cycle behaving and net-interest income holding as rates drift lower.
◆ Synthos call — WatchJPM is a business we want at a price we don't have — it becomes a Buy below ~$312; until then, do nothing.
Downside Risk (lower = safer)
4/10 · Moderate
Fortress balance sheet, 14.3% CET1, low double-digit P/E — but late-cycle credit and dead-flat beta-1 cyclicality.
Growth Quality
6/10 · High
~5-6% forward EPS CAGR, 23% ROTCE, best-in-class franchise — but mature, rate- and credit-cycle dependent.
Exponential Potential
3/10 · Low
A $896B bank near record highs; no acceleration, no TAM room to 5×. Own for compounding + capital return, not for exponential upside.
⚖ Reverse-DCF cross-checkMarket-implied growth ≈ 13%/yrTo justify today’s $334, earnings would have to compound roughly 13% a year for 10 years (9% discount rate). Analysts forecast ~8%/yr, so the market is pricing in MORE than what the Street expects.What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
JPMorgan (Chase) is the biggest bank in America. It runs your neighborhood Chase branch and credit card, and it is also the top Wall Street investment bank and a giant money manager — all under one roof. It makes money three ways: the gap between what it earns on loans and pays on deposits, fees from trading and advising companies, and fees for managing rich people's and institutions' money.
The stock is fairly priced, leaning slightly cheap — you pay about 14 dollars for every dollar the bank is expected to earn next year, which is low for such a high-quality company. Our verdict is Buy and hold it as a steady "core" position: a reliable, dividend-paying anchor, not a rocket ship.
Here's what our three scores mean in everyday terms:
Downside Risk 4/10 (fairly low). The bank is extraordinarily well-capitalized and cheap enough that there's a cushion — but it's a bank, so a recession that makes people stop paying loans would hurt it.
Growth Quality 6/10 (good, not great). A superb, extremely profitable franchise, but it's already huge and mature, so it grows slowly — think high-single-digits, not double.
Exponential Potential 3/10 (low). It's a nearly-$900-billion company near record highs. It compounds and pays you cash; it will not double overnight.
The one big worry: banks live and die by the credit cycle. If the economy weakens and more borrowers default, or if falling interest rates squeeze the gap the bank earns on loans, profits dip. JPMorgan is built to survive that better than anyone — but it is not immune.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLF (sector)), set to 100 a year ago
Solid = JPM · dashed = S&P 500 · dotted = XLF (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$334.47
Market cap$896B
P/E trailing15×
P/E FY26E / FY27E15× / 14×
EV / Sales6.4×
EV / EBITDA21.7×
Gross margin60.9%
Net margin20.7%
Dividend yield1.76%
Beta1
52-wk range$283 – $335
RSI(14)68
50 / 200-DMA$313 / $308
12-mo return+15% (SPY +21%)
Street target$341 ($295–$391)
Analyst grades31 Buy · 27 Hold · 2 Sell
FMP ratingB+
Next earnings2026-08-05
What the experts actually said 1 traceable claims on JPM · showing the highest-conviction voices
“JPMorgan is extraordinarily profitable ($150M/day, $57.5B FY2025) and dominant; a long-term shareholder shrugs off a boring call and post-earnings dip.”
Compound And Friendsbullishconviction 852026-01-13compound_and_friends-wPTInVH0d6o:6cbb1e410f
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
JPMorgan Chase & Co. (NYSE: JPM) is the largest US bank and a global financial holding company, founded 1799, run by CEO Jamie Dimon. It operates in three reported segments after its 2024 reorganization:
Consumer & Community Banking (CCB) — retail branches, deposits, cards, auto, home lending, small business.
Commercial & Investment Bank (CIB) — investment banking (M&A advisory, capital raising), markets/trading, payments, securities services, and commercial banking.
Asset & Wealth Management (AWM) — investment management and private banking for institutions and high-net-worth clients.
Fiscal year ends December 31. 316,864 employees.
Revenue mix (FY2025 segment net revenue, from filings):
Commercial & Investment Bank $78.5B · Consumer & Community Banking $76.0B · Asset & Wealth Management $24.1B · Corporate $7.0B (segment reconciling items −$3.1B). A genuinely diversified earnings base — the CIB/CCB balance is the reason JPM's ROTCE is steadier through cycles than a pure-play retail or investment bank.
By geography (FY2025): North America $139.7B (~78%) · EMEA $24.5B · Asia-Pacific $14.1B · Latin America $4.2B. US-centric, as expected for a domestic deposit franchise.
(Note on "revenue": FMP's headline "revenue" figure of $279.7B FY25 is gross interest income plus noninterest revenue. Banks are judged on total net revenue — ~$185B FY25 managed — which is what analyst estimates and this note use for growth/valuation math. 1Q26 total net revenue was $49.8B reported / $50.5B managed.)
2. The expert thesis — why the (thin) panel is constructive (traceable)
Honest breadth disclosure: JPM has near-zero expert coverage in the Synthos KB. There is exactly one distilled claim, from a single net-bullish voice. This verdict is therefore fundamentals- and quant-driven, not conviction-driven — the opposite of a name like LLY where 13 voices converge. Treat the expert layer here as a sanity check, not the thesis.
The one claim (bullish, conviction 85, skill 1.0):Compound & Friends (compound_and_friends-wPTInVH0d6o:6cbb1e410f, dated 2026-01-13) frames JPM as "extraordinarily profitable ($150M/day, $57.5B FY2025) and dominant; a long-term shareholder shrugs off a boring call and post-earnings dip." The point is the boring-is-good, own-the-compounder posture — which the fundamentals corroborate: FY25 net income was indeed $57.0B, and the franchise is dominant across CCB, CIB and AWM.
There is no cautionary voice in the KB for JPM either — absence of coverage cuts both ways. The bear case in §3/§11 is constructed from the data (cyclicality, credit, rate sensitivity), not from an expert.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
4 · Low-Moderate
14.3% CET1, 23% ROTCE and a ~14× forward P/E give real valuation and capital cushion; beta 1.0 and −19% max drawdown are contained. Offsetting: it is a cyclical bank near record highs, exposed to credit normalization and NII roll-down.
Growth Quality
6 · Good
ROTCE 23%, ROE 19%, diversified best-in-class franchise, buybacks shrinking the share count — but only ~5-6% forward EPS CAGR; mature, rate- and credit-cycle dependent.
Exponential Potential
3 · Low
A $896B bank near all-time highs with no growth acceleration and no TAM headroom to 5×. Own it for compounding + capital return, not for a multibagger.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores above summarize them.
Case
Key assumptions
Fair value
Bull
Soft landing; capital-markets/IB fees stay hot; NII holds up as deposit costs fall faster than asset yields; credit stays benign. FY27E EPS beats to ~$26 (vs $23.71 cons); multiple re-rates to a premium ~16.5×.
~$430 (+29%)
Base(our anchor)
Estimates roughly hit — FY27E EPS $23.71; a best-in-class bank earns a modest premium ~15×.
~$355 (+6%)
Bear
Recession/credit normalization; provisions spike; NII compresses as the Fed cuts; buybacks slow. FY27E EPS misses to ~$20; multiple de-rates to bank-cyclical ~12.5×.
~$250 (−25%)
Synthos fair value = the base case, ~$355 (+6%), with the full $250–$430 span as the honest range. This anchor sits essentially in line with the Street's $341 consensus — appropriate for a fairly-valued mega-cap where we have no informational edge from the panel. This is a tracked call — the Forecaster Scorecard grades it once it matures. Modest upside is the honest read: JPM is a quality hold near fair value, not a mispriced bargain.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). JPM is a premier compounder with essentially zero exponential character:
Forward growth: net-revenue CAGR FY25→FY28E ~5.2% (~$185B → $215B est); EPS CAGR ~5-6% ($20.09 FY25 → $25.94 FY28E est), flattered by ongoing buybacks shrinking the share count (diluted shares 2.79B, down from 3.03B in 2021).
Acceleration (the 2nd derivative) is flat-to-negative: EPS growth is decelerating from the post-2022 rate-driven surge (FY22 $12.10 → FY23 $16.25 → FY24 $19.79 → FY25 $20.09) toward a mid-single-digit cruise. There is no inflection ahead — the opposite of an exponential.
Room to run: at $896B market cap, the law of large numbers is decisive. JPM is already the largest US bank; a 5× implies a ~$4.5T bank, which is not a realistic outcome. Banking is a mature, share-taking game, not a TAM-expansion game.
Reinvestment runway: the bank returns most excess capital (buybacks + a ~1.8% dividend) rather than reinvesting for hypergrowth — correct at this scale, but definitionally not an exponential profile.
Exponential Potential: Low (3/10). Own JPM for durable mid-to-high-teens ROTCE compounding plus heavy capital return, not for a fast multibagger. Per our flagship philosophy we pick forward next-exponentials; JPM is a core-compounder holding, not a flagship exponential.
Earnings: FY25 net income $57.0B, EPS $20.09 (diluted $20.05), up from FY24 $58.5B/$19.79 — roughly flat net income, EPS higher on buybacks. FY23 $16.25, FY22 $12.10. Q1'26 net income $16.5B, EPS $5.94 (+17% YoY), beating the $5.47 estimate.
Total net revenue: ~$185B FY25 (managed); 1Q26 $50.5B managed (+10% YoY), led by CIB +21% net revenue with markets and IB fees (+31% IB fees YoY) both strong.
Profitability (best-in-peer): 1Q26 ROTCE 23%, ROE 19%, return on assets 1.41%. TTM ROE 16.3%. Net profit margin ~20.7% TTM on the net-revenue base.
Segment 1Q26 net income: CIB $9.0B · CCB $5.0B · AWM $1.8B · Corporate $0.7B — CIB doing the heavy lifting this quarter.
Capital return: FY25 buybacks ~$34.6B (share count 2.79B diluted vs 2.88B a year earlier) plus $16.6B common dividends; quarterly dividend raised to $1.50 (from $1.40). Payout ratio ~29% of earnings — plenty of headroom.
Balance sheet / capital: total assets $4.9T (1Q26). CET1 ratio 14.3% (Standardized) — a fortress, well above minimums. Book value/share $128.38, tangible book value/share $108.87 (1Q26), both compounding ~8% YoY.
Credit: 1Q26 provision for credit losses $2.5B (down 24% YoY); 4Q25 carried an elevated $4.7B provision that included $2.2B tied to the Apple Card portfolio acquisition. Total loans $1.50T, loans-to-deposits 56% — conservatively funded by a $2.68T deposit base.
(Bank cash-flow statements are noisy — FMP's "free cash flow" for a bank is not economically meaningful; ignore the −$42B FY24 operating-cash-flow figure, which is a balance-sheet-flow artifact, not a distress signal.)
6. Valuation — priced in or room?
JPM is reasonably valued, leaning slightly cheap for its quality:
Earnings: ~16× trailing EPS; forward 14.8× (FY26E) → 14.1× (FY27E) → 12.9× (FY28E) on consensus $22.57 / $23.71 / $25.94. For a bank earning 23% ROTCE, a low-14s forward multiple is not demanding.
Book value: P/B 2.6×, price-to-tangible-book ~3.1× ($334 / $108.87 TBVPS). That is a premium to the money-center peer group (most trade 1.0–1.6× tangible book) — but it is earned by JPM's superior and steadier ROTCE. The right way to read JPM is "you pay up on book because the returns on that book are elite."
Yield: dividend yield ~1.76% ($5.90/sh), plus a large buyback — total shareholder yield mid-single-digits.
Reverse read: at $334 the market is paying ~15× a mid-cycle ~$23 EPS. That prices in continued best-in-class execution but not heroics; the cushion is that a de-rate to 12–13× (bank-cyclical trough) only takes you to the mid-$250s, roughly our bear.
Street targets (context): consensus $341.25, high $391, low $295, median $342 — our $355 base sits right on top of consensus, which is honest: on a fairly-valued mega-cap with thin proprietary conviction we don't claim an edge over the Street. Grades: 1 Strong Buy, 31 Buy, 27 Hold, 2 Sell. Not a deep-value buy; a quality-franchise-at-a-fair-price buy.
7. Technicals (from the FMP tech block)
Trend:up but lagging the market. $334.47 sits above the 50-DMA ($312.61) and 200-DMA ($308.49), with the 50 above the 200 (golden-cross posture). MACD +6.8 (positive).
Location: just −0.2% off the 52-week high ($335.12), +18.3% off the 52-week low ($282.78) — a near-highs leadership posture with a shallow max drawdown of −19% from peak.
Momentum: RSI(14) 68 — strong and approaching overbought (<70), so entries here are slightly stretched; a pullback toward the rising 50-DMA (~$313) would be a lower-risk add.
Relative strength (the tell): JPM +15.2% 12-mo vs SPY +20.6% and QQQ +30.3% — underperforming both the broad market and tech over the past year (it did roughly match SPY over 3 months, +13.2% vs +13.7%). This is a market-lagging, mean-reverting mega-cap, not a momentum leader.
Read: technicals are constructive (uptrend, above both moving averages) but not screaming — near-highs, RSI elevated, and 12-month relative strength behind the market. No urgency to chase; scale in on weakness.
8. Moat & competitive position
JPMorgan's moat is scale + diversification + a deposit-cost advantage. Its ~$2.68T low-cost deposit base funds lending cheaply; its balance-sheet scale ($4.9T assets) lets it serve the largest corporates and win share in trading and investment banking; and the CCB / CIB / AWM diversification means no single revenue engine defines the cycle. The result is the group's best and steadiest ROTCE (23% in 1Q26) and a fortress 14.3% CET1 — the combination that lets JPM lean into stress (it acquired First Republic in 2023) while weaker banks retrench. Jamie Dimon's operating discipline is a genuine, if hard-to-model, intangible; the key-person question (eventual CEO succession) is the offsetting risk.
Peer set (market cap, from FMP): Bank of America $417B, HSBC $333B, Royal Bank of Canada $285B, Wells Fargo $262B, Citigroup $240B, Toronto-Dominion $202B, Bank of Montreal $122B, CIBC $106B, Bank of Nova Scotia $105B, Nu Holdings $66B. JPM is roughly 2× BAC and dwarfs the group; it commands the highest quality (ROTCE) and the richest tangible-book multiple in the set — justified by its returns, not a bubble.
9. Management, capital allocation & guidance
Capital allocation: exemplary and shareholder-friendly. FY25 returned ~$34.6B in buybacks + $16.6B dividends while growing the fortress balance sheet and lifting the dividend to $1.50/quarter. ~29% payout ratio leaves ample room. The January 2026 agreement for Chase to become the issuer of the Apple Card (forward purchase commitment, expected to close ~24 months out) is a scale bet on the card franchise — it drove a $2.2B provision build in 4Q25, so watch the credit and economics as it onboards.
Insider activity: the recent Form 4s in the window (through 2026-07-01) are routine director stock awards and officer RSU grants (e.g., director common-stock awards at $327.33; officer RSU grants at $0 cost) — not open-market discretionary selling. No alarming insider-selling cluster in the sampled window.
Management's own guidance (half-weighted — they talk their book): the SEC 8-K route returned JPM's 1Q26 earnings-release financial supplement (filed 2026-04-14). It is a real earnings release (full income statement, segment detail, capital ratios), but it is a data supplement rather than a forward-looking outlook narrative — it contains no explicit forward revenue or NII guidance in the retrieved text. Honest gap flagged: management's own forward NII / expense guidance (JPM typically guides full-year NII and adjusted expense on the call) was not captured in the 8-K supplement, so we do not summarize forward guidance here. What the supplement does confirm: 1Q26 ROTCE 23%, CET1 14.3%, net income $16.5B, and the Apple Card transaction timeline — all corroborating the fundamentals above.
10. Catalysts & what to watch
Next earnings: 2026-07-14 (Q2'26; Street EPS $5.49, revenue ~$49.8B). The key lines: net interest income trajectory (vs the Fed path) and credit provisions / net charge-off normalization.
Net interest income & the rate path: if the Fed cuts, deposit costs should fall but so do asset yields — the NII glide-path is the single biggest earnings swing factor.
Credit normalization: card and CRE charge-offs, and the reserve build as the Apple Card portfolio onboards.
Capital markets / IB fees: the CIB fee engine (IB fees +31% YoY in 1Q26) is the upside cyclical lever.
Capital return & CCAR: buyback pace and the next dividend action after the annual stress test.
Apple Card close (~2027): economics, credit quality, and integration.
Thesis tripwires (what would change the call): two consecutive quarters of sharply rising credit provisions; NII guidance cut materially; CET1 falling toward regulatory floors (forcing buybacks to stop); or a multiple re-rate above ~17× forward with no earnings acceleration (turn to Watch on valuation).
11. Key risks
Credit cycle (structural, cyclical): a recession that lifts loan losses is the classic bank risk; JPM is best-positioned but not immune. The Apple Card onboarding adds card-credit exposure.
Net-interest-income roll-down: falling rates compress the spread JPM earns; NII is a large share of revenue and rate-sensitive.
Cyclicality / beta 1.0: JPM moves with the economy and market; capital-markets revenue is inherently lumpy.
Valuation cushion is thin: at ~3.1× tangible book and near record highs, a growth or credit disappointment de-rates the stock (bear −25%).
Regulation & capital rules: Basel "endgame" capital requirements, stress-test outcomes, and political/regulatory scrutiny of the largest bank.
Key-person / succession: eventual Jamie Dimon succession is a real, if unscheduled, overhang on the premium multiple.
Thin expert coverage: only 1 KB voice — we lack the independent-panel corroboration that de-risks a conviction call. This is a quant/fundamentals verdict.
12. Verdict, position sizing & monitoring
Buy — Core. JPMorgan is the highest-quality large bank on earth — FY25 net income $57B, 1Q26 ROTCE 23%, a fortress 14.3% CET1, and ~$51B of FY25 capital return — trading at a reasonable ~14× forward earnings. The fundamentals and the (thin) expert layer point the same way; the quant profile (cheap-for-quality, well-capitalized, dominant) carries the call where the KB is nearly silent. Modest ~6% base-case upside means this is a hold-and-compound core position, not a mispriced bargain — own it for the ROTCE, the dividend, and the buyback, and add on cyclical weakness.
Sizing:core-cyclical, ~3–5% as the anchor financial holding. RSI 68 near 52-week highs argues for scaling in (starter now, adds toward the rising 50-DMA ~$313) rather than a lump at the high.
Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $334.47.
Single biggest risk: late-cycle credit normalization plus NII roll-down as rates fall — the two levers that turn a great bank into a merely good one for a couple of years.
Provenance & disclosures
Traceability: 1 KB claim, breadth 1, top skill 1.0 (Compound & Friends), last claim 2026-01-13 — reconciled to a real claim_id (compound_and_friends-wPTInVH0d6o:6cbb1e410f). Fabricated conviction is structurally impossible (claim-ID reconciliation). This is explicitly a low-breadth, fundamentals-/quant-driven note, not a high-conviction panel call.
Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · expert claim 2026-01-13. Forward figures are analyst consensus (FMP), labeled as estimates.
Bank-accounting caveat: FMP's headline "revenue" (gross interest income) and "free cash flow" are not the right lenses for a bank; this note uses total net revenue, EPS, ROTCE, and capital ratios.
Management caveat: the 8-K financial supplement is management's own data (half-weighted by design); it contained no explicit forward guidance, which we did not fabricate.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").